It is, therefore, becoming increasingly clear that targeting ERK pathways either through direct inhibition of ERK1/2 or inhibition of its upstream regulators shows therapeutic potential for the treatment of many inflammatory and autoimmune diseases. Here, MAPK3 is linked to autoimmune disease.